Cheung CY, Beardall MK, Anderson DF, Brace RA. Prostaglandin E 2 regulation of amnion cell vascular endothelial growth factor expression: relationship with intramembranous absorption rate in fetal sheep. Am J Physiol Regul Integr Comp Physiol 307: R354 -R360, 2014. First published June 4, 2014 doi:10.1152/ajpregu.00070.2014.-We hypothesized that prostaglandin E 2 (PGE2) stimulates amniotic fluid transport across the amnion by upregulating vascular endothelial growth factor (VEGF) expression in amnion cells and that amniotic PGE 2 concentration correlates positively with intramembranous (IM) absorption rate in fetal sheep. The effects of PGE 2 at a range of concentrations on VEGF 164 and caveolin-1 gene expressions were analyzed in cultured ovine amnion cells. IM absorption rate, amniotic fluid (AF) volume, and PGE 2 concentration in AF were determined in late-gestation fetal sheep during control conditions, isovolumic fetal urine replacement (low IM absorption rate), or intra-amniotic fluid infusion (high IM absorption rate). In ovine amnion cells, PGE 2 induced dose-and time-dependent increases in VEGF164 mRNA levels and reduced caveolin-1 mRNA and protein levels. VEGF receptor blockade abolished the caveolin-1 response, while minimally affecting the VEGF response to PGE 2. In sheep fetuses, urine replacement reduced amniotic PGE2 concentration by 58%, decreased IM absorption rate by half, and doubled AF volume (P Ͻ 0.01). Intraamniotic fluid infusion increased IM absorption rate and AF volume (P Ͻ 0.01), while amniotic PGE2 concentration was unchanged. Neither IM absorption rate nor AF volume correlated with amniotic PGE2 concentration under each experimental condition. Although PGE2 at micromolar concentrations induced dose-dependent responses in VEGF and caveolin-1 gene expression in cultured amnion cells consistent with a role of PGE 2 in activating VEGF to mediate AF transport across the amnion, amniotic PGE2 at physiological nanomolar concentrations does not appear to regulate IM absorption rate or AF volume. amniotic fluid volume; fetal urine; intramembranous absorption; prostaglandin E2; sheep
amniotic fluid volume; fetal urine; intramembranous absorption; prostaglandin E2; sheep AMNIOTIC FLUID (AF) IS A DYNAMIC reservoir with a rapid turnover in late gestation due to high inflows and outflows. The primary amniotic inflows are fetal urine and lung liquid, while the outflows include fetal swallowing and intramembranous (IM) transport of AF across the amnion into underlying fetal blood vessels (4, 20, 23) . Fetal urine production, lung liquid secretion, and swallowing have been well described and are regulated by fetal endocrine and nervous systems. The remaining major pathway, IM absorption, has been suggested as the key regulator of AF volume under a variety of experimental conditions (1, 6, 19, 34, 35) , but the regulation of IM absorption is currently poorly understood.
Previous studies have shown that the primary component of IM absorption is a unidirectional vesicular transcytosis of amniotic water and solutes across the amnion independent of osmotic and solute concentration differences. A secondary component is bidirectional and dependent on osmotic and solute concentration differences between AF and fetal blood (1, 5, 22) . Vascular endothelial growth factor (VEGF) has been shown to activate vesicular transcytosis in vascular endothelial cells (10) . Because the gene expression of VEGF in the amnion is elevated when IM absorption rate is increased above normal under various experimental conditions (12, 15, 19, 29) , VEGF may similarly mediate IM transport across the amnion. However, the factors that induce VEGF gene expression in the amnion have not been determined.
We recently demonstrated that fetal urine contains a substance that stimulates IM absorption in vivo (1) . The identity of this substance has not been elucidated, although it was shown not to be a major solute such as sodium or chloride, nor was it dependent on urine osmolality (1) . Fetal urine contains various proteins, endocrine factors, and cytokines in addition to the major solutes. One possible candidate for the unidentified renal derived IM stimulator is the eicosanoid prostaglandin E 2 (PGE 2 ). This possibility is supported by several observations. Casey et al. (7) found high concentrations of PGE 2 in human fetal urine and concluded that fetal urine is a source of prostanoids in AF. Further, Mitchell et al. (32) reported that human AF contains a fetal urine-derived substance that stimulates PGE 2 production in cultured amnion cells and suggested that "Such a process may be of fundamental importance in the regulation of amniotic fluid volume homeostasis."
Interactions of PGE 2 and VEGF have been reported under a variety of experimental conditions. PGE 2 or COX2 activation has been shown to increase VEGF gene expression in various cell types (11, 18, 26, 33, 38) . In addition to its angiogenic properties, VEGF is a potent cell permeability factor that stimulates transcellular transport via caveolae (10, 21) . In vascular endothelial cells, VEGF mediates its effect by downregulating the expression of caveolin-1, the caveolae structural protein (28) . Further, caveolin-1 may function as a negative regulator of VEGF receptor 2 (KDR) activity (27) . We have previously shown that VEGF and its KDR receptor are expressed in the ovine amnion (2, 3) . Further, in fetal sheep subjected to 4 days of hypoxic hypoxia, VEGF gene expression in amniotic epithelial cells was upregulated (29) , while caveolin-1 was suppressed (15) . Under such conditions, IM absorption rate was greatly increased. These observations are consistent with the notion that caveolin-1 negatively regulates AF transport across amnion cells (15, 35) . Thus, it is possible that PGE 2 in the AF would similarly activate VEGF production in the fetal membranes to enhance AF transport across the amnion by a caveolae-mediated vesicular process.
To explore the potential role of PGE 2 in regulating IM absorption and thus AF volume, we first determined the effects of PGE 2 on VEGF and caveolin-1 gene expression in cultured ovine amnion cells. Second, we analyzed the relationship between amniotic PGE 2 concentration, IM absorption rate, and AF volume in ovine fetuses under conditions of normal, low, or high IM absorption rates. We hypothesized that PGE 2 induces VEGF gene expression in amnion cells leading to downregulation of caveolin-1 expression. We further hypothesized that, in the ovine fetus, PGE 2 concentration in AF correlates positively with IM absorption rate and, therefore, negatively with AF volume, presumably through stimulation of the VEGFmediated transcytotic pathway in the amnion.
MATERIALS AND METHODS
Ethical approval. These studies were approved by our Institutional Animal Care and Use Committee. We followed the National Research Council's Guide for the Care and Use of Laboratory Animals.
Amnion cell culture and PGE 2 experiments. Fresh amnion tissues were obtained from late-gestation sheep [129 Ϯ 1 (SE) days gestation, term ϭ 145-150 days] with single or twin pregnancies. Amnion cells were prepared from minced amniotic membranes using three sequential treatments of 0.625% trypsin, as previously described (16) . The final cell pellet was resuspended in DMEM/F12 supplemented with 10% FBS and antibiotics, plated onto 75 mm 2 culture flasks, and maintained at 37°C in a humidified atmosphere of air and 5% carbon dioxide. At 90% confluence, the cells were seeded onto 6-well culture plates at 5 ϫ 10 5 cells per well. For the PGE2 experiments in amnion cells, the culture medium containing serum was withdrawn overnight and replaced with medium supplemented with 1 ϫ serum replacement (Cellgro, Mediatech, Voigt Global Distribution, Lawrence, KS). The cells were treated with 0.01 to 100 mol/l PGE 2 (1 mol/l ϭ 3.53 ϫ 10 5 pg/ml) for 3, 6, 24, or 48 h. At the end of each treatment period, cells were harvested for RNA and protein extraction. For VEGF antagonist experiments, amnion cells were pretreated with a specific mouse monoclonal VEGFR-2 receptor (KDR)-neutralizing antibody at 100 ng/l (MAB0701; Novus Biologicals, Littleton, CO) for 1 h prior to addition of PGE 2. Each amnion cell protocol was replicated in 3 to 6 experiments with triplicate wells per treatment group. Antagonist experiments for VEGFR-1 (Flt-1) blockade were not carried out since we have previously shown minimal expression of this receptor in ovine fetal membranes (3, 14) .
RT-PCR analysis of VEGF and caveolin-1. Amnion cell total RNA was extracted using the RNeasy Kit (Qiagen, Valencia, CA) and reverse transcribed using MuLV reverse transcriptase. Ten to fifteen micrograms of cDNA was used in a semiquantitative RT-PCR for determination of VEGF 164 mRNA levels with 18S ribosomal RNA as an internal reference, as previously described (15) . The procedure was optimized for efficiency to yield amplification products within the linear range of input cDNA (efficiency: 80 -85%; linearity: r ϭ 0.97). Because 18S rRNA was expressed in high abundance, an 18S Competimer (Ambion, Austin, TX) was used in the same PCR reaction to reduce the yield of 18S amplification product to levels similar to that for the target gene. A ratio of 1:29 (18S primer to Competimer) was found to be optimal and used in all subsequent VEGF PCR reactions (15) . The VEGF 164 primers used were forward: 5=-TGTAATGAC-GAAAGTCTGCAG-3= and reverse: 5=-CACCGCCTCGGCTTGT-CACA-3= (13) . The reaction was carried out for 28 cycles of 95°C for 15 s and 60°C for 30 s. Caveolin-1 mRNA levels were determined similarly by semiquantitative RT-PCR using L-19 as an internal reference in the same PCR reaction (15, 17) . Primers used were the following: for caveolin-1, forward, 5=-AACATCTACAAGCCCAA-CAACAAG-3= and reverse, 5=-CGCATCAACACGCAGAAA-GAAATA-3=; for L-19, forward, ATCGCCAATGCCAACTCCC-3= and reverse, 5=-GTCTGCCTTCAGCTTGTGG-3=. The reaction, optimized for efficiency and linearity, was carried out for 28 cycles of 55°C for 30 s and 72°C for 30 s. The amplified products were separated in 2% to 3% agarose gel and visualized with ethidium bromide staining. The intensity of the signal was quantified under ultraviolet light and analyzed by ChemiImager 4400 software (Alpha Innotech, San Leandro, CA).
Western immunoblotting for caveolin-1 protein. Protein lysates were obtained from amnion cells using a nondenaturing lysis buffer and quantified by the protein assay kit (Pierce, Rockford, IL). The proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes, as described previously (9, 17) . The blots were exposed to rabbit polyclonal anti-human caveolin-1 antibody (N-20, sc-894, Santa Cruz Biotechnology, Santa Cruz, CA) at 1:40,000 dilution. The secondary antibody used was a goat anti-rabbit IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology). The caveolin-1 protein was visualized with ChemiGlo substrate (Alpha Innotech) using the ChemiImager 4400 (Alpha Innotech). For internal reference, the membrane was stripped and reprobed for ␤-actin using a mouse monoclonal anti-human ␤-actin antibody (Santa Cruz Biotechnology) at 1:200 dilution. The intensity of the caveolin-1 signal was referenced to the ␤-actin signal.
Animals and surgical preparations. Eleven near-term pregnant sheep with singleton fetuses were surgically prepared, as previously described (34) . Briefly, a carotid artery catheter was placed for monitoring of blood gas status. Fetal urinary bladder and tracheal catheters were placed for sampling and flow rate measurements. A flow probe (Transonic Systems, Ithaca, NY) was placed on the midcervical esophagus for measuring swallowed volume. Multiple catheters were attached to the fetal skin for AF sampling and returning urine and lung liquid to the AF. In vivo data from some of these animals have been presented in part (1, 6) . The present study reports new data on PGE2 concentrations and relationships with AF volume and IM absorption rates.
Fetal sheep experimental methods. Experiments were conducted 5 or more days after surgery at a gestational age of 130 Ϯ 2 days. Fetuses were subjected to 2 or 3 successive 2-day experimental protocols in random order: 1) a control period with monitoring only (n ϭ 11); 2) continuous diversion of fetal urine to the exterior and isovolumic replacement with lactated Ringer solution (n ϭ 11); and 3) AF volume expansion by continuous intra-amniotic infusion of lactated Ringer at 2 l/day (1.4 ml/min, n ϭ 6). These conditions were chosen to experimentally alter AF volume and IM absorption rates, while modifying amniotic PGE2 concentrations within the physiological range. Alternative methodologies, such as indomethacin infusion to reduce PGE2 production or PGE2 infusion were avoided because of the associated conditions of ductus arteriosus constriction, fetal hypoxia, and reduction in urine production (8, 36) .
At the initiation of each experimental protocol, the AF compartment was emptied by drainage for measurement of AF volume and replaced with 1 liter of warm lactated Ringer solution, such that every protocol began with the same volume and composition of AF (1, 34) . During each 2-day protocol, fetal swallowing, urine flow rate, and lung liquid production rate were continuously monitored (34) . At the end of the 2-day protocol, samples of AF, fetal urine, and fetal lung liquid were collected for measurement of PGE2 concentration. PGE2 concentrations in fetal plasma were not determined, as PGE2 levels in fetal blood are much lower (less than half) than that in AF (37) and would not have significantly impacted the PGE 2 pool in the amniotic compartment. Prior to AF sampling, 20 -30 ml of AF were withdrawn from the sampling catheter before collection to ensure a mixed, representative AF sample was obtained. Fetal arterial blood was sampled for blood gases and pH measurements (Radiometer model 725 analyzer; Westlake, OH). AF volume was measured by drainage, and the IM absorption rate was calculated from the time-integrated amniotic inflows, outflows, and change in AF volume, as previously described (34) .
Prostaglandin E 2 determinations. Samples of AF, fetal urine, and lung liquid were subjected to centrifugation (AF, 1,800 g for 15 min; fetal urine, 3,000 g for 10 min; lung liquid, 1,500 g for 10 min) and filtered through 100-m filters to remove particulates and precipitants. The filtered fluid samples were quantified for PGE 2 concentration by ELISA (PGE 2 EIA kit; Cayman Chemical, Ann Arbor, MI). The inter-assay coefficient of variation was 8.4%, and the ED 50 averaged 50 pg/ml. Cross-reactivity of the monoclonal antibody for prostaglandin metabolites was less than 1%. Extraction of PGE 2 from the fluid samples prior to analysis was not performed because our initial analyses indicated that there was minimal interference of the standard values in the presence of filtered amniotic fluid or fetal urine. In addition, extraction of lung liquid samples using a PGE 2 affinity column kit (Cayman Chemical) yielded PGE 2 values comparable to the nonextracted samples. The values of extracted and nonextracted lung liquid samples differed by a mean of 16%, and the difference was not statistically significant by paired t-test.
Calculations, data presentation, and statistical analysis. VEGF and caveolin-1 mRNA levels are expressed relative to their respective 18S reference. Caveolin-1 protein amounts are expressed relative to the respective ␤-actin levels. Protein and mRNA levels were normalized to the respective values in control group with serum-replaced medium (SR) at 3 h of incubation. Urinary PGE2 excretion rate was calculated as the product of urine flow rate averaged over each 2-day protocol and urinary PGE 2 concentration. Lung PGE2 secretion rate was similarly calculated. The data were analyzed by one-and twofactor ANOVA or analysis of covariance (ANCOVA). When the ANCOVA found no difference, the data were combined. For the ANOVA, post hoc comparisons were made using Fisher's least significant difference for multiple comparisons when the null hypothesis was rejected. Least squares regression analyses were used to characterize relationships between variables. Values were logarithmically transformed to normalize variances as needed. Data are presented as the means Ϯ SE. A P value of 0.05 or less was considered significant.
RESULTS

PGE 2 effects on VEGF gene expression in amnion cells.
In amnion cells incubated with control medium containing serum replacement (SR), VEGF mRNA levels were unchanged over time (Fig. 1A) . At PGE 2 concentrations of 0.1 mol/l and lower, VEGF mRNA levels were not significantly altered. With increasing concentrations of PGE 2 , there was a significant increase in VEGF mRNA levels (P Ͻ 0.0001, Fig. 1A) . PGE 2 at concentrations of 1 mol/l and higher increased VEGF mRNA levels by 3 h (compared to level in the SR group at the same time point). At PGE 2 concentrations of 10 and 100 mol/l, the increases in VEGF mRNA were both time-(P Ͻ 0.05) and concentration-(P Ͻ 0.01) dependent, reaching peak levels with 100 mol/l at 24 h. The VEGF response declined at 48 h of treatment.
PGE 2 effects on caveolin-1 expression in amnion cells. Under control conditions, caveolin-1 mRNA levels did not change over time (Fig. 2A) . In response to PGE 2 treatment at 1, 10, and 100 mol/l, caveolin-1 mRNA levels in amnion cells decreased significantly compared with the SR group at 3 h, and the effects were time-(ANOVA P Ͻ 0.01) and concentration-(ANOVA, P Ͻ 0.01) dependent (Fig. 2A) . Maximal effect was achieved at PGE 2 concentration of 100 mol/l after 48 h of treatment. The decrease in caveolin-1 mRNA in the presence of increasing PGE 2 concentrations was paralleled by both timeand concentration-dependent reductions in caveolin-1 protein levels (P Ͻ 0.05, Fig. 3 ).
Following treatment of amnion cells with a VEGFR-2 neutralizing antibody at 100 ng/l, PGE 2 similarly increased VEGF mRNA levels (ANOVA, P Ͻ 0.0001, Fig. 1B) . At 1 and 10 mol/l PGE 2 , the responses were not different from those in the absence of antibody pretreatment. At 100 mol/l, the PGE 2 -induced increase in VEGF mRNA levels was moderately suppressed (ANOVA, P Ͻ 0.05) during neutralizing antibody treatment. In contrast, the PGE 2 -induced decrease in caveolin-1 mRNA levels was completely abolished in the presence of VEGFR-2 blockade at all PGE 2 concentrations tested over the 48-h experimental period (Fig. 2B) .
In vivo fetal sheep status. During the 2-day control period, fetal arterial pH, carbon dioxide tension, and oxygen tension averaged 7.347 Ϯ 0.006, 53.8 Ϯ 1.3 mmHg, and 22.4 Ϯ 0.8 mmHg, respectively. These values were unchanged during urine replacement and intra-amniotic fluid infusion.
Amniotic fluid, fetal urine, and lung liquid PGE 2 concentrations. During the control period, PGE 2 concentration in the AF was 887 Ϯ 111 pg/ml, significantly lower than 1,843 Ϯ 256 pg/ml in fetal urine but higher than 113 Ϯ 24 pg/ml in fetal lung liquid (ANOVA, P Ͻ 0.001). Fetal urine flow rate was 1,142 Ϯ 108 ml/day, and the calculated renal PGE 2 excretion rate was 2,086 Ϯ 254 ng/day. Lung liquid flow rate was 403 Ϯ 67 ml/day, and the calculated lung PGE 2 secretion rate was 44 Ϯ 10 ng/day. The lung PGE 2 secretion rate was equivalent to 4.8% Ϯ 3.1% of the amount of PGE 2 excreted by the kidneys. During diversion and isovolumic replacement of urine, urinary PGE 2 concentration was 1,386 Ϯ 176 pg/ml and was not significantly different from control. Amniotic PGE 2 concentration fell significantly to 348 Ϯ 50 pg/ml, which equaled 42% Ϯ 4% of control values (P Ͻ 0.05). This suggests that fetal urinary PGE 2 contributed 58% Ϯ 4% to the AF PGE 2 pool. Lung liquid PGE 2 concentration was 120 Ϯ 40 pg/ml, not different from the control value. On the basis of the data obtained during urine replacement, our calculations indicated that the lungs would have contributed only 2.5% Ϯ 1.5% to the amniotic PGE 2 pool under control conditions. Expansion of AF volume by continuous intra-amniotic infusion of lactated Ringer solution for 2 days did not significantly alter amniotic or urinary PGE 2 concentrations (AF ϭ 1,190 Ϯ 603 pg/ml; urine ϭ 2,355 Ϯ 545 pg/ml). Similarly, fetal lung liquid PGE 2 concentration (104 Ϯ 21 pg/ml) was not affected by intraamniotic fluid infusion.
Amniotic fluid and urinary PGE 2 concentration relationships. Fetal urine and amniotic PGE 2 concentrations were positively correlated during control conditions and during intra-amniotic infusion. The urinary and amniotic PGE 2 concentrations remained positively correlated when urine was diverted and replaced, even though fetal urine did not enter the AF. When the three groups were compared, there were statistically significant shifts in the relationships between amniotic and urinary PGE 2 concentrations (ANCOVA, P Ͻ 0.05, Fig. 4) . These changes were due to decreases in amniotic PGE 2 concentrations during urine replacement, resulting in a downward shift in the regression line (ANCOVA, P Ͻ 0.01 compared with control). In contrast, during intra-amniotic infusion, neither amniotic PGE 2 concentrations nor the relationship between AF and urinary PGE 2 concentrations were different from the control (ANCOVA, P ϭ ns). No correlation was found between amniotic and lung liquid PGE 2 concentrations or secretion rates under any of the three experimental conditions.
Amniotic fluid volume, intramembranous absorption rate, and amniotic PGE 2 concentration relationships. Under control conditions, IM absorption rate (963 Ϯ 118 ml/day) and AF volume (776 Ϯ 134 ml) were negatively correlated (r ϭ Ϫ0.61, P Ͻ 0.05). During urine diversion and replacement, AF volume doubled (P Ͻ 0.001), and IM absorption rate decreased by 57% Ϯ 11% (P Ͻ 0.001). However, the negative relationship between AF volume and IM absorption rate (r ϭ Ϫ0.58, P Ͻ 0.01 for the combined urine replacement and control groups) was not altered (ANCOVA, P ϭ 0.25). During intraamniotic fluid infusion, AF volume and IM absorption rate both increased significantly and remained negatively correlated (r ϭ Ϫ0.96, P Ͻ 0.01). However, in response to fluid infusion, the relationship between AF volume and IM absorption rate shifted upward and to the right due to the large increases in both AF volume and IM absorption rate (ANCOVA, P Ͻ 0.0001, Fig. 5 ).
IM absorption rate and amniotic PGE 2 concentration were not significantly correlated under each of the three experimental conditions (Fig. 6A) . Similarly, AF volume and amniotic PGE 2 concentration were not significantly correlated (Fig. 6B) . Further, the changes in neither IM absorption rate nor AF volume were correlated with the changes in amniotic PGE 2 concentration. When analyzed collectively, the regression relationship between IM absorption rate and amniotic PGE 2 concentration shifted significantly downward with urine replacement and upward during intra-amniotic fluid infusion (ANCOVA, P Ͻ 0.001, Fig. 6A ). These changes were due to alterations in IM absorption rate independent of PGE 2 concentration. Comparable results were obtained by analysis of the relationships between AF volume and amniotic PGE 2 concentrations (ANCOVA, P Ͻ 0.001, Fig. 6B ). The upward shifts in the regression lines for the urine replacement and infusion groups were due to changes in AF volume independent of PGE 2 concentration. These results were not altered by either exclusion of the one outlier with high amniotic PGE 2 concentrations in Fig. 6 or by log transformation of the data (after excluding the one negative IM absorption rate in Fig. 6A ).
When analyzed against renal PGE 2 excretion rate rather than amniotic PGE 2 concentration, similar results were obtained in that neither IM absorption rate nor AF volume were correlated with PGE 2 excretion rate during control conditions or during intra-amniotic fluid infusion (data not shown). As expected, there were no significant correlations during urine diversion and replacement when urine did not enter the AF. There was no significant correlation between IM absorption rate or AF volume and lung liquid PGE 2 concentrations under any of the experimental conditions studied.
DISCUSSION
An objective of this study was to explore whether PGE 2 , a prostanoid abundant in fetal urine, would alter VEGF and caveolin-1 gene expression in amnion cells and potentially function as the stimulator of IM absorption present in fetal sheep urine (1) . Our study demonstrated that PGE 2 not only upregulated VEGF gene expression and downregulated caveolin-1 expression in ovine amnion cells in vitro, as hypothesized, but also that the PGE 2 effect on caveolin-1 was mediated though the VEGFR-2 receptor. These observations are consistent with the established role of VEGF in stimulating vesicular transcytosis via caveolae (10) , and in downregulating caveolin-1 expression observed in vascular endothelial cells (28) .
Further, these findings support our earlier report that increases in IM absorption induced by hypoxia was associated with elevated VEGF but reduced caveolin-1 gene expression in the amnion (15) .
Our second objective was to examine the relationship between amniotic PGE 2 concentrations and IM absorption rate in chronically catheterized ovine fetuses under experimental conditions of normal, low, or high IM absorption rates. On the basis of our in vitro findings in amnion cells, we expected that amniotic PGE 2 concentrations would correlate positively with IM absorption rate in vivo, presumably through the activation of VEGF-mediated transcytotic pathways. However, our present studies in ovine fetuses do not support the functionality of such a pathway because neither amniotic PGE 2 concentration, urinary PGE 2 concentration, nor renal PGE 2 excretion rate correlated with IM absorption rate or AF volume under control and experimentally induced conditions of decreased or increased IM absorption. The lack of relationship likely is due to the in vivo concentrations of PGE 2 in AF (250 -1,000 pg/ml or 1-4 nmol/l) being lower than the effective dose of PGE 2 in the in vitro amnion cell studies (1,000 -100,000 nmol/l). Thus, under normal physiological conditions, amniotic PGE 2 would not be involved in the maintenance of IM transport and, thus, of AF volume. However, participation of PGE 2 in the regulation of AF dynamics may occur under adverse conditions when amniotic PGE 2 is greatly elevated, such as during intrauterine infection when fetal and amniotic PGE 2 concentrations reach ϳ20 times normal in pregnant sheep (24) and ϳ120 times normal in Rhesus monkeys (25) .
In addition to our original objectives, the present study has provided several unique observations regarding PGE 2 levels in Fig. 6 . ANCOVA comparison of relationships between amniotic fluid PGE2 concentration and intramembranous (IM) absorption rate (A) and amniotic fluid volume (B). denotes control conditions, OE denotes fetal urine replacement, denotes 2 l/day intra-amniotic infusion of lactated Ringer solution. With the one outlier excluded, P Ͻ 0.001 for panels A and B. When log transformed to normalize variances, P Ͻ 0.01 for panels A and B, after excluding the one negative IM absorption rate in panel A (log data not shown). OE denotes fetal urine replacement, and denotes continuous 2 l/day intraamniotic infusion of lactated Ringer solution. Data from control and urine replacement groups were combined prior to analysis because the regression relationship between these two groups was unaltered by urine replacement (ANCOVA, P ϭ 0.25).
the AF compartment. In near-term ovine fetuses under normal conditions, amniotic PGE 2 concentrations are high, while urinary levels are twice amniotic levels. The fetal kidneys normally excrete more than 40 times as much PGE 2 as the fetal lungs secrete into the AF. With high renal excretion rates, it is not unexpected that a positive correlation existed between urinary and amniotic PGE 2 concentrations under control conditions and during intra-amniotic fluid infusion. These results are consistent with the notion that fetal urinary PGE 2 is a primary contributor to the PGE 2 pool in AF. However, the observation that amniotic and urinary PGE 2 concentrations remained positively correlated but shifted downward when fetal urine was replaced with Ringer solution was not expected and suggests that amniotic PGE 2 and urinary PGE 2 levels are regulated by a common endogenous factor presumably present in the fetal circulation. This observation requires further investigation.
Because fetal urine contributes about 58% to the amniotic PGE 2 pool, while lung liquid contributes 3%, the remaining PGE 2 in AF must be derived from other sources. Because PGE 2 concentration in ovine fetal blood is low compared with AF concentrations (37), the fetal vascular system would be a sink rather than source of amniotic PGE 2 . The most likely source would be endogenous production by the fetal membranes and, to a lesser extent, the umbilical cord (30, 31) . Our finding that amniotic PGE 2 concentration during urine replacement was much higher than could be explained by a pulmonary source alone also supports this possibility.
Perspectives and Significance
Although it has long been recognized that AF volume is regulated by the rate of IM absorption, presently there is no detailed knowledge of the factors involved in modulating IM transport across the amnion and into the underlying fetal vasculature. Over the past decade, the most significant advance in this understanding has been the observations that IM transport across the amnion has two components: a primary unidirectional vesicular transcytosis of AF mediated by VEGF and a secondary passive bidirectional diffusion of water and solutes down concentration and osmotic gradients between AF and fetal blood through aquaporin water channels. The recent observation that fetal urine contains a stimulator of IM absorption (1) raised the possibility that PGE 2 is the unidentified renal stimulator of IM absorption across the amnion. This is because PGE 2 is present in fetal urine in high concentrations, and PGE 2 is known to stimulate cellular VEGF expression and function. However, in contrast to our hypothesis, PGE 2 does not appear to be involved in the regulation of AF volume under physiological conditions. Thus, the stimulator of IM absorption present in fetal urine remains to be identified.
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